Theravance Biopharma (TBPH) Projected to Announce Quarterly Earnings on Tuesday

Key Points

• Theravance Biopharma is expected to report Q3 2026 results before the market opens Tuesday, November 10. Analysts project earnings of $0.24 per share on revenue of $21.95 million.
• The company’s previous quarter fell short of expectations, reporting a loss of $0.11 per share versus the estimated profit of $0.07 and revenue of $20.73 million against the $22.49 million consensus.
• TBPH shares were recently flat at $17.03, while analysts maintain a consensus “Hold” rating and an average price target of $19.00.

Theravance Biopharma (NASDAQ:TBPH - Get Free Report) is anticipated to issue its Q3 2026 results before the market opens on Tuesday, November 10th. Analysts expect Theravance Biopharma to announce earnings of $0.24 per share and revenue of $21.95 million for the quarter. Investors are encouraged to explore the company's upcoming Q3 2026 earnings results page for the latest details on the call scheduled for Monday, November 2, 2026 at 12:30 PM ET.

Theravance Biopharma (NASDAQ:TBPH - Get Free Report) last released its quarterly earnings results on Monday, August 10th. The biopharmaceutical company reported ($0.11) earnings per share for the quarter, missing analysts' consensus estimates of $0.07 by ($0.18). The business had revenue of $20.73 million for the quarter, compared to analysts' expectations of $22.49 million. Theravance Biopharma had a negative return on equity of 0.77% and a net margin of 51.58%. On average, analysts expect Theravance Biopharma to post $1.56 EPS for the current fiscal year and $0.81 EPS for the next fiscal year.

Theravance Biopharma Stock Performance

TBPH stock remained flat at $17.03 during mid-day trading on Tuesday. The firm has a fifty day moving average price of $17.03 and a 200 day moving average price of $16.99. Theravance Biopharma has a 1 year low of $13.08 and a 1 year high of $21.03. The stock has a market capitalization of $884.18 million, a price-to-earnings ratio of 16.86 and a beta of 0.25.

Insider Transactions at Theravance Biopharma

In other Theravance Biopharma news, SVP Rhonda Farnum sold 13,314 shares of the stock in a transaction dated Tuesday, September 15th. The stock was sold at an average price of $17.03, for a total value of $226,737.42. Following the sale, the senior vice president owned 213,476 shares of the company's stock, valued at $3,635,496.28. This trade represents a 5.87% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 7.65% of the stock is owned by corporate insiders.

Analyst Ratings Changes

Several equities analysts have weighed in on the company. Zacks Research downgraded Theravance Biopharma from a "strong-buy" rating to a "hold" rating in a research report on Monday, September 7th. BTIG Research dropped coverage on shares of Theravance Biopharma in a research note on Thursday, September 24th. They issued a "neutral" rating for the company. HC Wainwright cut shares of Theravance Biopharma from a "buy" rating to a "neutral" rating and lifted their price objective for the company from $15.00 to $17.00 in a report on Tuesday, July 7th. Finally, Weiss Ratings raised shares of Theravance Biopharma from a "hold (c)" rating to a "hold (c+)" rating in a research note on Monday, August 17th. Seven research analysts have rated the stock with a Hold rating. Based on data from MarketBeat.com, Theravance Biopharma has a consensus rating of "Hold" and an average price target of $19.00.

About Theravance Biopharma

Theravance Biopharma, Inc is a biopharmaceutical company focused on discovering, developing and commercializing medicines for serious diseases, with an emphasis on respiratory disorders and other conditions where there is a significant unmet medical need. The company's research and development activities have historically centered on therapies designed to improve lung function and address chronic respiratory disease.

Its principal marketed product is Yupelri (revefenacin), a once-daily nebulized long-acting muscarinic antagonist for the maintenance treatment of chronic obstructive pulmonary disease (COPD).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.